Bioxel Pharma Inc.

Bioxel Pharma Inc.

October 11, 2006 08:00 ET

Bioxel Patents Pharmaceutical Platform for Targeted Chemotherapy

SAINTE-FOY, QUEBEC--(CCNMatthews - Oct. 11, 2006) - Bioxel Pharma Inc.(TSX VENTURE:BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, is pleased to announce the filing of a patent application on a pharmaceutical technology designed to improve transport and tumor targeting of anticancer drugs.

One of the major objectives in chemotherapy is to achieve high tumor accumulation of drugs in order to maximize treatment efficacy. Unfortunately, as a result of their toxicity, many anticancer drugs are administered at doses below their optimum therapeutic level. Bioxel Pharma, in collaboration with renowned pharmaceutical experts Dr. Jean-Christophe Leroux, at the University of Montreal, and Dr. Christine Allen from the University of Toronto, has developed an injectable nano-emulsion carrier that has the potential to enhance drug accumulation at the tumor site and reduce drug distribution to healthy tissues.

Bioxel's nano-emulsion technology is a promising drug carrier due to its biocompatibility, ability to dissolve lipophilic drugs and the relative ease of manufacture at an industrial scale. Animal studies have shown that these nano-emulsions exhibit prolonged blood circulation time, are effective at targeting neoplastic tissues and provide enhanced accumulation in tumors.

"This proprietary pharmaceutical platform represents a major step forward as Bioxel now has the capability to develop in partnership with pharmaceutical companies a portfolio of oncology products using already marketed drugs" said Pascal Delmas, President and CEO of Bioxel Pharma. In the coming months, Bioxel will identify anticancer agents that can be more effectively formulated using this nano-emulsion technology, and define the best strategy to assemble a strong pharmaceutical and pre-clinical dossier on a first drug candidate.

Bioxel currently manufactures and sells natural cGMP paclitaxel to specialty pharmaceutical companies and generic formulation manufacturers. The Corporation's dedicated cGMP facility is located at an FDA inspected pharmaceutical manufacturing site. Bioxel's paclitaxel is registered with US, EU and Canadian regulatory authorities, allowing its use worldwide.

The Corporation also develops docetaxel, the active ingredient used in Taxotere®, a chemotherapy drug marketed by Sanofi-Aventis which generated worldwide sales of US$2.2 billion in 2005. The first patents on docetaxel will expire at the end of 2007, paving the way for the development of generic Taxotere®. Bioxel is actively pursuing commercial discussions with pharmaceutical companies that will ensure the efficient manufacturing and distribution of its docetaxel product.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients and proprietary products for improved cancer therapy. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information